{"filing":{"accession_number":"0001193805-26-001277","cik":"0001768224","ticker":"ARCT","company_name":"Arcturus Therapeutics Holdings Inc.","form":"8-K","filing_date":"2026-09-23","report_date":"2026-09-23","primary_document":"e665798_8k-arct.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1768224/000119380526001277/e665798_8k-arct.htm"},"events":[{"id":34586,"run_id":31830,"accession_number":"0001193805-26-001277","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The disclosure centers on interim Phase 2 clinical data for ARCT-810 showing encouraging safety and biomarker results, introduction of LUNAR 2.0™ platform with 30-40 fold improvement in protein expression, and announcement of the myNEO acquisition to enhance mRNA design capabilities. While clinical progress and platform advancement are operationally significant, this is a Regulation FD disclosure (Item 7.01) of clinical and strategic updates rather than a discrete financial, governance, or legal event. The material clinical milestones and platform innovation warrant classification as operational_other rather than a more specific category.","company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","filing_date":"2026-09-23","form":"8-K","submitted_at":null,"items":[{"id":38347,"accession_number":"0001193805-26-001277","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure centers on interim Phase 2 clinical data for ARCT-810 showing encouraging safety and biomarker results, introduction of LUNAR 2.0™ platform with 30-40 fold improvement in protein expression, and announcement of the myNEO acquisition to enhance mRNA design capabilities. While clinical progress and platform advancement are operationally significant, this is a Regulation FD disclosure (Item 7.01) of clinical and strategic updates rather than a discrete financial, governance, or legal event. The material clinical milestones and platform innovation warrant classification as operational_other rather than a more specific category.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-23T20:14:57.801098+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":38347,"accession_number":"0001193805-26-001277","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure centers on interim Phase 2 clinical data for ARCT-810 showing encouraging safety and biomarker results, introduction of LUNAR 2.0™ platform with 30-40 fold improvement in protein expression, and announcement of the myNEO acquisition to enhance mRNA design capabilities. While clinical progress and platform advancement are operationally significant, this is a Regulation FD disclosure (Item 7.01) of clinical and strategic updates rather than a discrete financial, governance, or legal event. The material clinical milestones and platform innovation warrant classification as operational_other rather than a more specific category.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-23T20:14:57.801098+00:00","company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","filing_date":"2026-09-23"}]}